Large Inflow of Money Witnessed in Geron Corporation

Geron Corporation (NASDAQ:GERN) : Investors lapped up stocks on upticks to the tune of $0.2 million in the Wednesdays trading session. The trading value on downticks was comparatively at $0.12 million and the uptick to downtick ratio of 1.76 indicates continuous buying by the bulls. The net money flow into the stock was $0.09 million. Upticks saw transactions worth $0.05 clearly indicating buying by large investors. The total money flow for block trades stood at $0.05 million, which is a positive for the stock in the long-term. Geron Corporation (NASDAQ:GERN) fell $0.03 during the day at $2.61, a drop of -1.14% over the previous days close. However, for the week, the stock is 0.77%, compared to the previous week.


In an insider trading activity, The officer (EVP, Chief Financial Officer), of Geron Corp, Bloom Olivia Kyusuk had unloaded 2,380 shares at $3.84 per share in a transaction on May 29, 2015. The total value of transaction was $9,139. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing. Currently the company Insiders own 5.82% of Geron Corporation shares according to the proxy statements. Institutional Investors own 42.46% of Geron Corporation shares.

The company shares have dropped -40.00% from its 1 Year high price. On Dec 2, 2015, the shares registered one year high at $5.30 and the one year low was seen on Feb 26, 2016. The 50-Day Moving Average price is $2.79 and the 200 Day Moving Average price is recorded at $3.13. Geron Corporation (NASDAQ:GERN): The stock was completely flat for the day, closing at $2.64 on Wednesday. The flat closing masks the intraday volatility in the stock. After opening at $2.68, the stock touched an intraday high of $2.70 and a low of $2.60. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $2.64. The total trading volume on Wednesday was 2,326,737.

Geron Corporation (Geron) is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides a capacity for limitless, uncontrolled proliferation. Telomerase consists of two essential components: a ribonucleic acid (RNA) template (hTR), which binds to the telomere, and a catalytic subunit (hTERT) with reverse transcriptase activity, which adds a specific DNA (deoxyribonucleic acid) sequence to the chromosome ends. Using its nucleic acid chemistry, the Company designed imetelstat to be an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.